Ilsung Pharm Cash Flow-to-Debt Ratio
Ilsung Pharm cash flow-to-debt ratio. Ilsung Pharm (003120) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2026, meaning its operating cash flow of ₩124.28 Million could theoretically repay 0% of its total liabilities (₩14.27 Billion) in one year. Check earnings quality score of Ilsung Pharm to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Ilsung Pharm (2013–2025)
Cash flow-to-debt ratio of Ilsung Pharm from 2013 to 2025. Historical debt coverage capacity for Ilsung Pharm across 13 annual periods. Check total reinvestment intensity of Ilsung Pharm to assess the company's total reinvestment commitment from operating cash flow.
Ilsung Pharm Cash Flow-to-Debt Ratio by Year (2013–2025)
Ilsung Pharm cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Ilsung Pharm. For the full cash flow conversion analysis, see Ilsung Pharm operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | ₩3.88 Billion | ₩16.67 Billion | ▲ +164.3% |
| 2024 | -0.36x | ₩-4.26 Billion | ₩11.75 Billion | ▲ +68.2% |
| 2023 | -1.14x | ₩-41.47 Billion | ₩36.44 Billion | ▼ -42.7% |
| 2022 | -0.80x | ₩-38.97 Billion | ₩48.85 Billion | ▼ -456.2% |
| 2021 | 0.22x | ₩5.70 Billion | ₩25.47 Billion | ▲ +241.5% |
| 2020 | 0.07x | ₩1.56 Billion | ₩23.75 Billion | ▼ -64.1% |
| 2019 | 0.18x | ₩4.39 Billion | ₩24.03 Billion | ▼ -72.2% |
| 2018 | 0.66x | ₩15.09 Billion | ₩22.93 Billion | ▲ +59.6% |
| 2017 | 0.41x | ₩10.16 Billion | ₩24.64 Billion | ▲ +124.5% |
| 2016 | -1.69x | ₩-31.01 Billion | ₩18.40 Billion | ▼ -1458.3% |
| 2015 | 0.12x | ₩6.04 Billion | ₩48.69 Billion | ▲ +47.1% |
| 2014 | 0.08x | ₩4.19 Billion | ₩49.69 Billion | ▼ -16.9% |
| 2013 | 0.10x | ₩5.06 Billion | ₩49.92 Billion | — |